Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method

(2014) David Polidori et al.   Theoretical Biology and Medical Modelling

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study

(2013) Kaj Stenlöf et al.   CURRENT MEDICAL RESEARCH AND OPINION

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

(2013) J. P. H. Wilding et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

(2013) David Polidori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

(2013) Damayanthi Devineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Achievement of Goals in U.S. Diabetes Care, 1999–2010

(2013) Mohammed K. Ali et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Quantification of the effect of energy imbalance on bodyweight

(2011) Kevin D Hall et al.   LANCET

Body Fluid Volumes and the Response of Renin and Aldosterone to Short- and Long-Term Thiazide Therapy of Essential Hypertension

(2010) P. Brummelen et al.   ACTA MEDICA SCANDINAVICA

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

(2009) Harold Bays   CURRENT MEDICAL RESEARCH AND OPINION

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Impact of the time window on plasma volume measurement with indocyanine green

(2008) M Jacob et al.   PHYSIOLOGICAL MEASUREMENT

SLC2A9 Is a High-Capacity Urate Transporter in Humans

(2008) Mark J Caulfield et al.   PLOS MEDICINE